drugset

drugset / Trial / NCT05642923

Post-COVID-19 Chronic Fatigue Syndrome

NCT05642923 ↗

Phase 4 Completed 528 enrolled ClinAmygate As-Salam Center, Maadi, Cairo, Egypt · collab

RandomizedParallel-groupSingle-blindTreatment

Summary

Fatigue is recognized as one of the most commonly presented long-term complaints in individuals previously infected with SARS-CoV-2.

Timeline

Start: 2023-01-08
Primary completion: 2024-06-01
Completion: 2025-03-05

Publications

Background Jackson C. The Chalder Fatigue Scale (CFQ 11). Occup Med (Lond). 2015 Jan;65(1):86. doi: 10.1093/occmed/kqu168. No abstract available.
Results Kedor C, Freitag H, Meyer-Arndt L, Wittke K, Hanitsch LG, Zoller T, Steinbeis F, Haffke M, Rudolf G, Heidecker B, Bobbert T, Spranger J, Volk HD, Skurk C, Konietschke F, Paul F, Behrends U, Bellmann-Strobl J, Scheibenbogen C. A prospective observational study of post-COVID-19 chronic fatigue syndrome following the first pandemic wave in Germany and biomarkers associated with symptom severity. Nat Commun. 2022 Aug 30;13(1):5104. doi: 10.1038/s41467-022-32507-6.

Drugs

Evaluation	Drug	Modality	Dose	Route
Comparator	Synthetic Vitamin B1	Unknown	400 mg	—

Indications